Halozyme Therapeutics stock is trading -26.38% below its average target price of $48.56 after marking a 3.4% during today's afternoon session. Analysts are giving the mid-cap Biotechnology company an average rating of buy and target prices ranging from $26.0 to $66.0 per share.
Halozyme Therapeutics has an average level of shares sold short, at 6.3% of its total share float. The stock's short ratio (also called days to cover) is 5.39. Only 0.91% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Institutional investors own 97.7% of Halozyme Therapeutics's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Halozyme Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Blackrock Inc. | 14% | 18,145,852 | $648,714,209 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 10% | 13,519,639 | $483,327,094 |
| 2023-03-31 | Artisan Partners Limited Partnership | 5% | 6,992,189 | $249,970,756 |
| 2023-03-31 | State Street Corporation | 5% | 5,954,775 | $212,883,206 |
| 2023-03-31 | Snyder Capital Management, LP | 3% | 4,295,184 | $153,552,828 |
| 2023-03-31 | JP Morgan Chase & Company | 3% | 3,522,776 | $125,939,242 |
| 2023-03-31 | Invesco Ltd. | 3% | 3,491,177 | $124,809,577 |
| 2023-03-31 | Macquarie Group Limited | 2% | 3,200,481 | $114,417,195 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 2,631,387 | $94,072,085 |
| 2023-03-31 | GW&K Investment Management, LLC | 2% | 2,402,115 | $85,875,611 |
